title: Successful treatment of resistant pseudogout with anakinra.
abstract: We describe herein the case of a 63-year-old man with pseudogout affecting multiple joints that was resistant to treatment with allopurinol, steroids, and antiinflammatory drugs. Based on recent data on the molecular mechanism of pseudogout that demonstrated overproduction of interleukin-1 (IL-1), we treated the patient with anakinra, an IL-1 receptor antagonist. The patient responded to treatment with anakinra within 2 weeks, with resolution of the signs and symptoms of pseudogout and normalization of levels of inflammation markers.
authors.affiliation: Calderdale Royal Hospital, Halifax, UK. d.g.mcgonagle@leeds.ac.uk
authors.forename: Dennis
authors.initials: D
authors.lastname: McGonagle
authors.forename: Ai Lyn
authors.initials: AL
authors.lastname: Tan
authors.forename: Julie
authors.initials: J
authors.lastname: Madden
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
authors.forename: Michael F
authors.initials: MF
authors.lastname: McDermott
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D015415:Biomarkers; D002805:Chondrocalcinosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D008875:Middle Aged
chemical_list: D018501:Antirheumatic Agents; D015415:Biomarkers; D053590:Interleukin 1 Receptor Antagonist Protein